Download PDF AVEO’s Human Response Prediction Platform to Guide Clinical Development of Multiple Kinase Inhibitor CAMBRIDGE, MA January 5, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that AVEO has acquired from Mitsubishi Pharma Corporation an exclusive license to develop and commercialize Mitsubishi’s novel